Research
Research Interest 1
The research themes of the Antimicrobial Pharmacodynamics and Therapeutics Laboratory are as follows:
1. Development of New Antimicrobial Agents
2. Repurposing and Optimisation
3. Antimicrobials for Neonates and Children
4. Antimicrobials for Neglected Tropical Diseases
5. Individualisation of Antimicrobial Therapy
Details of each research theme can be found at Antimicrobial Pharmacodynamics and Therapeutics
Research grants
Extending the utility and durability of antifungal agents via innovative combination regimens that minimise drug resistance
MEDICAL RESEARCH COUNCIL
February 2024 - January 2029
Development of a new rabbit model to characterise antifungal drug resistance
FOOD AND DRUG ADMINISTATION (USA)
September 2023 - September 2025
Fleming Fund Fellowship Fund
THE FLEMING FUND (UK)
February 2024 - December 2025
Pharmacodynamics of Cefiderocol for MDR/XDR Gram Negative Pathogens
GARDP FOUNDATION (SWITZERLAND)
November 2023 - June 2027
Data Accelerator Project (System P & AMR-X)
NHS CHESHIRE AND MERSEYSIDE ICB (UK)
December 2023 - October 2027
MICA: EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
MEDICAL RESEARCH COUNCIL
June 2023 - May 2025
Biomarker Driven Antifungal Stewardship in AML: The BioDriveAFS Trial
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
September 2021 - April 2026
Centres for Antimicrobial Optimisation Network – UK (CAMO-Net UK) (CAMO-Net UK)
WELLCOME TRUST (UK)
April 2023 - March 2026
Phase II PK/PD driven dose finding trial of Praziquantel in children under four
NATIONAL INSTITUTES OF HEALTH (USA)
January 2021 - June 2024
Novel Gram-Negative Antibiotic Now (T7.2 & T7.4) (GNA NOW)
EUROPEAN COMMISSION
July 2019 - December 2025
Pharmacokinetic-Pharmacodynamic assessment of BV100 in the hollow fibre infection model WP1
BIOVERSYS (SWITZERLAND)
April 2021 - February 2025
Smart Antimicrobial System (SAS) to provide actionable information to tackle Antimicrobial Resistance
PFIZER INC (USA)
April 2021 - June 2022
Expansion of assessment pharmacodynamics of flomoxef-fosfomycin and fosfomycin/amikacin combinations for neonatal sepsis using the HFIM
GARDP FOUNDATION (SWITZERLAND)
August 2022 - March 2024
ANT3310 - Assessment of the pharmacodynamics of ANT3310 a serine beta-lactamase inhibitor
ANTABIO (FRANCE)
January 2020 - December 2020
Pharmacodynamics of Amphotericin B Cochleates for Cryptococcal Meningitis
MATINAS BIOPHARMA NANOTECHNOLOGIES, INC (USA)
April 2017 - July 2017
Pharmacodynamics of Tebipenem
SPERO OPCO INC (USA)
August 2016 - July 2018
High Dose AMBISOME© on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomized Controlled Non-inferiority Trial (AMBITION)
EUROPEAN AND DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP) - (NETHERLANDS)
January 2017 - October 2021
Pharamcodyanmics of new antimicrobial agents for neonatal meningitis
FOOD AND DRUG ADMINISTATION (USA)
September 2016 - September 2019
Assessment of tebipenem in the hollow fibre
SPERO OPCO INC (USA)
August 2016 - July 2018
ADAPT
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
September 2019 - March 2022
Pharmacodynamics of Meropenem and metallobetalactmase inhibitors against NDM producing Gram Negatives
ANTABIO (FRANCE)
September 2017 - February 2018
Pharmacodynamics of Antimicrobial Combinations for Neonatal Sepsis in Low-To-Middle Income Countries
DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI) (SWITZERLAND), GARDP FOUNDATION (SWITZERLAND)
November 2018 - July 2021
AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers REC
ALLECRA THERAPEUTICS GMBH (GERMANY)
January 2018 - September 2022
PK-PD analyses of cefepime and AAI101 against MDR enterobacteriaceae
ALLECRA THERAPEUTICS GMBH (GERMANY)
October 2017 - October 2018
Pharmacokinetic-Pharmacodynamic analyses of novel metallo-betalactmase inhibitors in multidrug resistant Gram negative infections
ANTABIO (FRANCE)
May 2018 - October 2019
Assessment of the PKPD of BWC0977
BUGWORKS RESEARCH INDIA PVT. LTD. (INDIA)
September 2019 - June 2025
Spatially-resolved PKPD modelling for optimised treatment of central nervous system infection due to Mycobacterium tuberculosis
MEDICAL RESEARCH COUNCIL
August 2016 - July 2019
Rational Design, Synthesis and Biological Evaluation of Benzimidazoles Towards a Novel Therapy Selectively Targeting C. neoformans beta-tubulin
MEDICAL RESEARCH COUNCIL
July 2016 - December 2019
Centre for Antimicrobial Pharmacodynamics
INNOVATE UK (UK)
January 2017 - March 2017
Pharmacodynamics of Novel Potentiators Against Multidrug Resistant Gram Negative Infections
SPERO OPCO INC (USA)
August 2016 - July 2017
Combatting Bacterial Resistance in Europe COMBACTE-MAGNET
AICURIS GMBH (GERMANY), EUROPEAN COMMISSION
January 2015 - December 2022
Pharmacodynamics of Novel Antifungal Agents Against Aspergillus fumigatus
F2G LTD (UK)
May 2013 - June 2016
Pharmacodynamics of Voricamozole against fusarium SPP and scedosporium apiospermum: Identification of in vitro suscepibility breakpoints and targets for theraputic drug monitoring
EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (SWITZERLAND)
June 2013 - May 2014
Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off‐patent antibiotics
EUROPEAN COMMISSION
April 2013 - November 2016
Towards complete sustained release nanoformulations of NRTI based regimens
NATIONAL INSTITUTES OF HEALTH (USA)
July 2014 - June 2019
Generating Micafungin amd Isavuconazole MICs Versus Candida spp. using EUCAST Methodology
ASTELLAS PHARMA GLOBAL DEVELOPMENT (USA)
August 2012 - July 2013
A Control Theory Approach for Individualisation of Antifungal dosing in Immunocomprised Patients
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
June 2012 - September 2016
Treatment of late onset bacterial sepsis caused by Vancomycin susceptible bacteria in neonates and infants aged under three months (NeoVanc)
EUROPEAN COMMISSION
February 2014 - July 2020
Cryptococcal meningitis: addressing an urgent global health problem using a translational pharmacological approach
MEDICAL RESEARCH COUNCIL
December 2012 - February 2015